These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 1865139)

  • 1. [Hypophosphatemia and hyperphosphatemia].
    Ogura Y
    Nihon Naika Gakkai Zasshi; 1991 Feb; 80(2):185-9. PubMed ID: 1865139
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of hyperphosphatemia in chronic renal failure].
    Babarykin DA; Afanas'eva GA; Shul'man OM; Luse LIa; Rozental' RL
    Ter Arkh; 1984; 56(7):64-6. PubMed ID: 6484838
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical disorders of phosphorus metabolism.
    Yu GC; Lee DB
    West J Med; 1987 Nov; 147(5):569-76. PubMed ID: 3321712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hypophosphatemia. Clinical and biological consequences, diagnostic and therapeutic strategies].
    Leke L; Kochert F; Krim G; Risbourg B
    Arch Fr Pediatr; 1991; 48(7):495-505. PubMed ID: 1929752
    [No Abstract]   [Full Text] [Related]  

  • 5. RenaGel efficacy in severe secondary hyperparathyroidism.
    Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
    Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hydroxyproline in the dialysate as a parameter of secondary hyperparathyroidism. Effects of phosphate reduction and alkalization].
    Schiessl JH; Schweigart U; Bottermann P; Kopp KF
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1310-3. PubMed ID: 25525
    [No Abstract]   [Full Text] [Related]  

  • 7. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.
    Gutierrez O; Isakova T; Rhee E; Shah A; Holmes J; Collerone G; Jüppner H; Wolf M
    J Am Soc Nephrol; 2005 Jul; 16(7):2205-15. PubMed ID: 15917335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Methods of correcting hyperphosphatemia in chronic renal failure and in dialysis (review)].
    Novikov AI
    Ter Arkh; 1997; 69(12):63-7. PubMed ID: 9503540
    [No Abstract]   [Full Text] [Related]  

  • 9. [Front line of management of hyperphosphatemia in hemodialysis patients].
    Yumita S
    Clin Calcium; 2004 May; 14(5):771-7. PubMed ID: 15577041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis of secondary hyperparathyroidism in chronic renal insufficiency.
    Portale AA; Morris RC
    Miner Electrolyte Metab; 1991; 17(4):211-20. PubMed ID: 1813783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Disorders of calcium and phosphorus metabolism in renal failure and nephrotic syndrome].
    Kubota M; Ohno T
    Nihon Rinsho; 1982; 40(12):2673-9. PubMed ID: 6761460
    [No Abstract]   [Full Text] [Related]  

  • 13. [Radioimmunologic determination of circulating parathyroid hormone in patients with primary and secondary hyperparathyroidism].
    Lo Giudice C; Cascone C; Manente P; Gasparoni P; De Luca M; Rota G; Conte N
    Minerva Med; 1982 Dec; 73(48):3425-8. PubMed ID: 7177469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphate binders in hyperphosphatemia of chronic renal failure.
    Wasan SM; Godley PJ
    DICP; 1991 Sep; 25(9):942-5. PubMed ID: 1949972
    [No Abstract]   [Full Text] [Related]  

  • 15. [Hyperphosphoremia and hypophosphoremia].
    Kuntziger H; Altman JJ
    Rev Prat; 1989 Apr; 39(11):949-53. PubMed ID: 2717867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease.
    Salusky IB; Foley J; Nelson P; Goodman WG
    N Engl J Med; 1991 Feb; 324(8):527-31. PubMed ID: 1992306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperphosphatemia in Chinese peritoneal dialysis patients with and without residual kidney function: what are the implications?
    Wang AY; Woo J; Sea MM; Law MC; Lui SF; Li PK
    Am J Kidney Dis; 2004 Apr; 43(4):712-20. PubMed ID: 15042549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there increasing evidence to change the management of renal bone disease?
    Harum P
    Nephrol News Issues; 1999 Apr; 13(4):55-6. PubMed ID: 10418451
    [No Abstract]   [Full Text] [Related]  

  • 19. [Characteristics of phosphorus metabolism in patients with acute disorders of cerebral circulation].
    ChepkiUi LP; Pas'ko SA; Volosheniuk TG; Sofienko GI
    Vrach Delo; 1989 Dec; (12):27-9. PubMed ID: 2629271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Control of hyperphosphatemia among patients with ESRD.
    Coladonato JA
    J Am Soc Nephrol; 2005 Nov; 16 Suppl 2():S107-14. PubMed ID: 16251245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.